The "Kidney Transplant Rejection R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com's offering.
This review describes the pipeline of drugs under development for Kidney Transplant Rejection, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Kidney Transplant Rejection Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Kidney Transplant Rejection disease overview, Kidney Transplant Rejection types, Kidney Transplant Rejection symptoms, causes, and FDA/EMA approved treatment options.
Kidney Transplant Rejection Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Kidney Transplant Rejection indication. The report presents near-term and long-term pipeline development trends and potential insights.
Kidney Transplant Rejection Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 30 companies. Business profiles and contact details of the companies actively perusing Kidney Transplant Rejection pipeline are assessed.
Kidney Transplant Rejection R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Kidney Transplant Rejection discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Kidney Transplant Rejection companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Kidney Transplant Rejection pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Kidney Transplant Rejection Pipeline Market News and Developments during 2020
The Kidney Transplant Rejection industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Kidney Transplant Rejection Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Scope and Coverage
Kidney Transplant Rejection pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
Company-company partnerships, company-institute partnerships, and investment details of companies are included
30 companies are included
Disease overview, Pipeline trends, market analysis, and other developments
Potential licensing/new business opportunities in Kidney Transplant Rejection pipeline market
Global coverage of companies and pipeline agents
2020 Trends, market analysis, and developments
Potential growth opportunities
Comprehensive details of drug candidates
Key Topics Covered:
1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Kidney Transplant Rejection Pipeline Trends and Insights
2.1 Dominant Phase type of Kidney Transplant Rejection Pipeline, 2020
2.2 Most focused Mechanism of Action in Kidney Transplant Rejection Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Kidney Transplant Rejection pipeline
2.5 Active Companies Developing Kidney Transplant Rejection pipeline
3. Kidney Transplant Rejection Disease Types, Symptoms, Causes, and Available Treatment Options
3.1 Disease Overview
3.4 Approved Treatment Options
4. Kidney Transplant Rejection Pipeline Company Trends and Insights- Business Profiles, Drug Candidates and Contacts
AlphaMab Co Ltd
Amyndas Pharmaceuticals LLC
Astellas Pharma Inc
Bristol-Myers Squibb Co
Corline Biomedical AB
Gilead Sciences Inc
Hansa Medical AB
Helocyte Biosciences Inc
Hillhurst Biopharmaceuticals Inc
ITB Med AB
JN Biosciences LLC
Kiniksa Pharmaceuticals Ltd
Kyowa Hakko Kirin Co Ltd
Medeor Therapeutics Inc
NextCell Pharma AB
Pharmicell Co Ltd
Talaris Therapeutics Inc
Tract Therapeutics Inc
Veloxis Pharmaceuticals AS
Viela Bio Inc
5. Kidney Transplant Rejection Pipeline Drug Profiles
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.2 Mechanism of Action
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. Kidney Transplant Rejection Pipeline Market News and Developments during 2020
For more information about this report visit https://www.researchandmarkets.com/r/uop9m8
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029006031/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900